Blockchain Registration Transaction Record
Soligenix's HyBryte Shows Promising Results in Treating Rare Skin Cancer
Soligenix (NASDAQ: SNGX), a biopharmaceutical company, reveals promising results for its lead candidate, HyBryte, in treating rare skin cancer. With a 75% response rate in clinical trials, HyBryte shows potential as a groundbreaking therapy for cutaneous T-cell lymphoma.

This news matters as it highlights the potential breakthrough in treating cutaneous T-cell lymphoma, a rare and challenging form of skin cancer. The success of HyBryte, with its high response rate in clinical trials, offers hope to patients and showcases the innovative approach of Soligenix in addressing unmet medical needs.
Blockchain | Details |
---|---|
Contract Address | 0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71 |
Transaction ID | 0xc43b55efefdbdbe0a1991d59e324d4354bd8b5d931e6bbb36218843522ff61c5 |
Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
Chain | polygon-main |
NewsRamp Digital Fingerprint | ovalF0X8-94c478276878e3cfaf19ccc6333ecd45 |